Edition:
United Kingdom

Biospecifics Technologies Corp (BSTC.OQ)

BSTC.OQ on NASDAQ Stock Exchange Global Market

45.07USD
15 Dec 2017
Change (% chg)

$2.18 (+5.08%)
Prev Close
$42.89
Open
$42.74
Day's High
$45.29
Day's Low
$42.74
Volume
31,283
Avg. Vol
7,236
52-wk High
$58.36
52-wk Low
$41.95

Summary

Name Age Since Current Position

Thomas Wegman

60 2009 President, Principal Executive Officer, Principal Financial Officer, Director

Mark Wegman

65 2007 Director

Toby Wegman

80 2007 Director

Jennifer Chao

45 2015 Independent Director

Paul Gitman

74 1990 Independent Director

Jyrki Mattila

62 2015 Independent Director

Michael Schamroth

75 2004 Independent Director

Biographies

Name Description

Thomas Wegman

Mr. Thomas L. Wegman is President, Principal Executive Officer, Principal Financial Officer, Director of Biospecifics Technologies Corp. He has served as an officer of the Company for 15 years. He is current President and has served as President since October 17, 2005. Prior to such appointment, he served as the Executive Vice President of the Company. Effective in 1994, Mr. Wegman became a director on the Board of the Company and has served as such since that time. He has 30 years of experience in the bio-pharmaceutical industry that encompasses managing company operations and drug development, licensing, and registration. Mr. Wegman has had experience managing the production, marketing and foreign registration activities related to an avian vaccine business. Mr. Wegman has been instrumental in licensing technologies from universities for use by the Company. He is the author of a number of U.S. and foreign patents in the life sciences field. Mr. Wegman received his B.A. from Boston University in 1977.

Mark Wegman

Dr. Mark N. Wegman, Ph.D., is Director of Biospecifics Technologies Corp., since June 25, 2007. He joined International Business Machines (“IBM”) in 1975 where Dr. Wegman is currently Chief Scientist Software Technology with world wide responsibilities in IBM’s Research laboratories. Dr. Wegman is recognized for his contributions to computer algorithms and compiler optimization that have areas of computer science and practice. This work was recognized by the Special Interest Group On Programming Languages in 2006 with its Programming Languages Achievement Award. He is an IBM Fellow, which is IBM’s highest technical honor, and a Fellow of the ACM and the IEEE. He is also a member of the National Academy of Engineering. Dr. Wegman is the author of 30 publications in the field of Computer Science. Dr. Wegman received his doctorate in Computer Science from the University of California at Berkeley.

Toby Wegman

Ms. Toby Wegman is Director of Biospecifics Technologies Corp., since June 25, 2007. Ms. Wegman is the widow of the former CEO and Chairman, Edwin H. Wegman. Ms. Wegman has had a range of business-related work experiences. For five years she owned and operated a women’s apparel business and prior to that managed a women’s retail clothing operation. She had been in the management of Edwin H. Wegman’s business interests and finances for many years.

Jennifer Chao

Ms. Jennifer M. Chao is an Independent Director of the Company. Ms. Jennifer Chao is an Advisory Analyst at CoreStrategies Management, LLC, a strategic consulting firm she founded in 2008 focused on providing transformational strategy and maximizing corporate valuation. Previously, she served as Managing Director and Senior Analyst, Biotechnology at Deutsche Bank, Managing Director and Senior Analyst, Biotechnology at RBC Capital Markets, and Senior Analyst, Biotechnology at Leerink Swann. Ms. Chao is a biotechnology industry expert having covered small-, mid-, and large-cap biotechnology companies with a forte on cutting edge technologies, evolving clinical algorithms, and game-changing treatment modalities. She received her B.A. from New York University and was a Research Fellow and recipient of the 1996/1997 Massachusetts General Hospital/Harvard Medical School Biomedical Research Career Award.

Paul Gitman

Dr. Paul A. Gitman, M.D., is an Independent Director of Biospecifics Technologies Corp., since 1990. He is board certified by the American Board of Internal Medicine and the American Board of Quality Assurance and Utilization Review. Following 25 years in private medical practice he joined the fulltime faculty of Long Island Jewish Medical Center where he was Medical Director and later Vice President of Medical Affairs for the North Shore Long Island Jewish Health System until 2009. Dr. Gitman is an Associate Professor of Medicine at Albert Einstein College of Medicine as well as the Chairman of the Medical Society of the State of New York’s Committee for Physician’s Health. He has served on the New York State Board of Medicine for 10 years and on various New York State Committees and Task Forces. He is past President of both the New York Chapter of the American College of Physicians and the Medical Society of the County of Queens. Dr. Gitman received his medical degree from Boston University School of Medicine.

Jyrki Mattila

Dr. Jyrki Mattila, M.D. Ph.D. is an Independent Director of the Company. Dr. Jyrki Mattila has served as Chief Business Officer at iCeutica Inc. since October 2013. Prior to joining iCeutica, from 2010 to 2013, Dr. Mattila served as President and CEO of LZ Therapeutics, Inc. Before that, he was Executive Vice President of Business Development, Product Development and Technical Operations at Auxilium Pharmaceuticals, Inc. Dr. Mattila previously served in a series of positions with increasing seniority at Orion Corporation, including as President of Orion Pharma, where under his leadership several innovative products were developed and commercialized in global markets. He has negotiated and closed over 50 business agreements, including licensing, co-marketing, collaboration and product acquisition arrangements. Dr. Mattila received his M.D. and a Ph.D. in Pharmacology from the University of Helsinki Medical School and his M.B.A. from the Helsinki School of Economics. Dr. Mattila completed his post-doctoral research fellowship at the University of Kansas Medical Center.

Michael Schamroth

Mr. Michael Schamroth is an Independent Director of Biospecifics Technologies Corp., since February 2004. He has been a partner of M. Schamroth & Sons in New York City for over 40 years. As a principal in this fourth-generation international diamond house, Mr. Schamroth has experience in dealing with all aspects of the trade, from manufacturing to sales. He has been a member of the Diamond Manufacturers and Importers Association since 1964, and has served on the Nominating and Building Committees of the Diamond Dealers Club. In addition, Mr. Schamroth has served as a member of the Board of South Nassau Communities Hospital since 1976, the Board of the Winthrop-South Nassau University Health System since 1993 and the Board of Sound Bank of North Carolina since 2002. He has been a member of the Miami University Business Advisory Board since 1984 and served as its Chairman from 1987-1988. He received his B.S. in Business from Miami University, Oxford, Ohio.

Basic Compensation

Name Fiscal Year Total

Thomas Wegman

353,325

Mark Wegman

--

Toby Wegman

--

Jennifer Chao

--

Paul Gitman

--

Jyrki Mattila

--

Michael Schamroth

--
As Of  31 Dec 2014

Options Compensation